1. Home
  2. VERI vs MAIA Comparison

VERI vs MAIA Comparison

Compare VERI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veritone Inc.

VERI

Veritone Inc.

N/A

Current Price

$0.48

Market Cap

57.7M

Sector

Technology

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.06

Market Cap

69.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VERI
MAIA
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.7M
69.2M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
VERI
MAIA
Price
$0.48
$1.06
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$4.50
★ $12.00
AVG Volume (30 Days)
★ 3.8M
294.1K
Earning Date
11-12-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
N/A
★ N/A
Revenue
★ $92,637,000.00
N/A
Revenue This Year
$11.05
N/A
Revenue Next Year
$33.37
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.87
52 Week High
$6.13
$3.19

Technical Indicators

Market Signals
Indicator
VERI
MAIA
Relative Strength Index (RSI) 33.63 40.87
Support Level N/A N/A
Resistance Level $0.67 $1.48
Average True Range (ATR) 0.06 0.06
MACD 0.01 -0.00
Stochastic Oscillator 18.09 20.00

Price Performance

Historical Comparison
VERI
MAIA

About VERI Veritone Inc.

Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: